17133-54-9

Basic information

• Product Name: (3,4-Dihydro-2H-quinolin-1-yl)-acetic acid Methyl ester
• Synonyms: (3,4-Dihydro-2H-quinolin-1-yl)-acetic acid Methyl ester;Methyl 2-(3,4-dihydroquinolin-1(2H)-yl)acetate
• CAS NO: 17133-54-9
• Molecular Formula: C12H15NO2
• Molecular Weight: 205.253
• Mol File: 17133-54-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (3,4-Dihydro-2H-quinolin-1-yl)-acetic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (3,4-Dihydro-2H-quinolin-1-yl)-acetic acid Methyl ester(17133-54-9)
• EPA Substance Registry System: (3,4-Dihydro-2H-quinolin-1-yl)-acetic acid Methyl ester(17133-54-9)

Safety Data

• Hazardous Substances Data: 17133-54-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3,4-Dihydro-2H-quinolin-1-yl)-acetic acid Methyl ester is used as a synthetic intermediate for the development of pharmaceuticals. Its potential pharmacological activities make it a promising candidate for drug discovery and therapeutic applications in various diseases.
Used in Agrochemical Industry:
(3,4-Dihydro-2H-quinolin-1-yl)-acetic acid Methyl ester is also used as a synthetic intermediate in the production of agrochemicals. Its potential applications in this industry may include the development of pesticides, herbicides, or other agricultural chemicals to improve crop yield and protect against pests.
Overall, (3,4-Dihydro-2H-quinolin-1-yl)-acetic acid Methyl ester is a chemical compound with potential applications in both the pharmaceutical and agrochemical industries, and its ongoing research and development aim to unlock its full potential in these fields.

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 96-32-2 bromoacetic acid methyl ester 
• 16695-14-0 Malonic acid monomethyl ester 
• 108-59-8 malonic acid dimethyl ester 
• 96-34-4 methyl chloroacetate 
• 767-92-0 decahydroquinoline 

Relevant articles and documents

Inactivation of myostatin by photo-oxygenation using catalyst-functionalized peptides

Inhibition of myostatin is an attractive treatment for muscular dystrophy and other amyotrophic diseases. A myostatin-binding peptide was functionalized by equipped with an on/off switchable photo-oxygenation catalyst. This peptide induces a selective oxygenation of myostatin under near-infrared light, resulting in inactivation of myostatin. This peptide shows several orders of magnitude greater inhibitory effect than the original peptide.

BORON-DIPYRRIN COMPLEX AND PHARMACEUTICAL PRODUCT CONTAINING SAME

Provided are a compound which is useful as an in vivo applicable, amyloid-oxygenating catalyst selective for amyloid and applicable not only to an Aβ peptide, but also to other amyloids and a drug containing the compound for preventing and/or treating amyloid-related diseases. Disclosed is a boron-dipyrrin complex represented by the following formula (1) wherein X1 and X2 are the same or different and each represent a halogenoalkyl group or a halogen atom; R1 represents a hydrogen atom, an alkyl group, or a group represented by formula (b): R2 and R6 are the same or different and each represent a hydrogen atom or a halogen atom; R3, R4, R5, and R7 are the same or different and each represent a hydrogen atom, a halogen atom, or an alkyl group; R8 represents a hydrogen atom or -(CH2)l-(Y)m-(CH2)n-Z wherein Y represents -CO-, -CONH-, or a triazole ring, Z represents a carboxyl group, a sulfonic acid group, or a -CO-peptide residue, 1 and n each represent an integer of 1 to 6, and m represents 0 or 1; R9 and R10 are the same or different and each represent a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, an amino group, a nitro group, or a cyano group; and R8 and R10 together optionally form an alkylene group.

Transition-metal-free decarboxylation of dimethyl malonate: An efficient construction of α-amino acid esters using TBAI/TBHP

A transition-metal-free decarboxylation coupling process for the preparation of α-amino acid esters, which succeeded in merging hydrolysis/decarboxylation/nucleophilic substitution, is well described. This strategy uses commercially available inexpensive starting materials, catalysts and oxidants and has a wide substrate scope and operational simplicity. This journal is

A new strategy for the construction of α-amino acid esters via decarboxylation

A new α-amino acid esters formation reaction has been developed via decarboxylation. The methodology is distinguished by its practical novelty in terms of the readily accessible starting materials, environmentally benign reaction conditions and waste streams, and wide substrate scope.

Pharmaceutical compounds

This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals.

Compounds that modulate PPAR activity and methods of preparation

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.